Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

OMS643762 · OMS824

Small molecule · developed by Omeros

Phase 2 Most advanced trial (none active)
OMER Developer
1 Registered trials

What is OMS643762?

OMS643762 is an investigational small-molecule drug studied in Schizophrenia.

At a glance

Also known as
OMS824
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Omeros Corporation (OMER)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01952132 Phase 2 Schizophrenia Completed OMER

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

More from Omeros

Narsoplimab FDA approved OMS103HP Phase 3 OMS103HP-S Phase 3 OMS201 Phase 1/2 Zaltenibart Phase 2

Follow OMER, the company behind OMS643762

See OMER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OMER catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.